Loading
Saturday, October 17, 2026 · Vol. I, No. 42Independent · Canadian · Research-first
Before you compare Canadian research sourcesRun the free 10-point COA + batch audit at LynxLabs →
Cagrilintide · research summary
Advances in therapy · 2026. Summary drawn from the study's full text. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.
Narrative review
“This narrative review discusses strategies to improve the effectiveness of pharmacotherapy and bariatric surgery and posits that bariatric surgery will continue to play an important role in obesity treatment in the GLP1RA era.”
Adults with obesity
“Obesity is a chronic disease that continues to increase in prevalence worldwide and is estimated to reach a global prevalence of 54% in adults by 2035 [1, 2].”
GLP1RA have real-world limitations including discontinuation, cost, and tolerability.
“GLP1RA have real-world limitations in practice, including discontinuation, cost, and tolerability.”
Bariatric surgery will likely remain part of the treatment armamentarium for obesity despite widespread use of GLP1RA.
“Bariatric surgery will likely remain part of the treatment armamentarium for obesity despite widespread use of GLP-1 receptor agonists (GLP1RA) based on access, efficacy, and the trajectory of obesity phenotypes.”
Source: PubMed 41627368 · DOI 10.1007/s12325-026-03494-7 · all study summaries